Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any unusual grants.) .... | 33,247,849 | 38,582,579 | 57,556,516 | 56,251,128 | 58,810,206 | 244,448,278 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 33,247,849 | 38,582,579 | 57,556,516 | 56,251,128 | 58,810,206 | 244,448,278 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 6,057,646 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 238,390,632 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 33,247,849 | 38,582,579 | 57,556,516 | 56,251,128 | 58,810,206 | 244,448,278 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 897,974 | 755,293 | 804,366 | 1,652,775 | 1,316,372 | 5,426,780 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 1,624,966 | 1,467,184 | 1,693,833 | 2,103,589 | 2,246,081 | 9,135,653 |
| 11 | Total support. Add lines 7 through 10. | 259,010,711 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2015 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2015 |
(iii) Distributable Amount for 2015 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2015 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2015 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2015: | ||||
| a | ||||
| b | ||||
| c | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2015 distributable amount | ||||
|
i
Carryover from 2010 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2015 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2015 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2015, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2015. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2016. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a | ||||
| b | ||||
| c Excess from 2013....... | ||||
| d From 2014....... | ||||
| e From 2015....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| Program Service Accomplishments(1) | Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the U.S. National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the pursuit of a cure for HIV/AIDS. Countdown to a Cure for AIDS In 2015, amfAR announced a $100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy represents an unprecedented expansion of amfAR's grant making and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development. It is structured to provide sustained support for a wide range of studies that advance both emerging and established ideas. The strategy comprises the following components: - amfAR Institute for HIV Cure Research established in 2016 with a 20 million grant over five years to the University of California, San Francisco, the Institute is the cornerstone of amfAR's cure research efforts. - Innovation Grants These two-year awards of up to $200,000 each enable researchers to test innovative ideas supported by limited preliminary data. - Impact Grants These grants of up to $2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure. - Investment Grants Aimed at recruiting the experience and expertise of scientists from outside the field of HIV, these $1 million grants are awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience or inflammatory disease that can directly inform efforts to cure HIV. - ARCHE Launched in 2010, the amfAR Research Consortium on HIV Eradication, or ARCHE, supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. - Opportunity Fund This funding mechanism will enable amfAR to respond quickly to emerging and unforeseen research opportunities. In just the first 24 months of the Countdown to a Cure for AIDS initiative, amfAR has supported 139 principal investigators and key personnel in 16 U.S. states and nine other countries around the world. Innovation Grants In June, amfAR announced a new round of Innovation Grants, totaling close to $1.4 million, to allow scientists to better understand why HIV persists in the body despite effective antiretroviral therapy and pursue novel pathways to a cure. The round of grants was supported in part by the Foundation for AIDS and Immune Research (FAIR). Among the grantees is Dr. Jonathan Karn of Case Western Reserve University in Cleveland, Ohio, who is aiming to develop a more accurate, cost - and time-efficient way to measure the size of the viral reservoir, which is essential for gauging the effectiveness of potentially curative interventions. Karns method could reduce the need for burdensome blood draws and greatly increase the number of patients who can be tested at one time. Another grantee, Dr. Maud Mavigner of Emory University in Atlanta, is conducting a comprehensive study to identify the most accurate methods to measure the viral reservoir in rhesus macaques infected with SIV, the non-human primate equivalent of HIV. SIV-infected rhesus macaques have helped answer some of the most crucial questions in HIV research. And a third grantee, Dr. Celsa Spina of the University of California, San Diego, is studying how and where HIV inserts itself into our DNA, enabling it to establish the hidden viral reservoir. The particular region can help determine whether the virus actively replicates or remains latent. The results of Spinas research will be important as we develop new drugs to target this reservoir. Investment grants In January 2016, amfAR awarded $1 million each over four years to Harvard physicist Dr. David Weitz and bioengineer and polymer scientist Dr. Alexander Zelikin of Aarhus University in Denmark. The two will collaborate with leading HIV researchers Drs. Bruce Walker and Martin Tolstrup at Harvard and Aarhus, respectively, in the effort to eradicate the viral reservoir, which is considered the principal barrier to curing HIV. Weitz proposes to isolate the most effective T cells from those that are less potent, clone them in a petri dish, and use a mouse model to test whether the reinjection of these killer cells can lead to a functional cure for HIV. An expert in prodrugs, Zelikin will design a two-component cocktail - one will gently reawaken the latent HIV and the second will specifically initiate the killing of virally infected cells. ARCHE (amfAR Research Consortium on HIV Eradication) In October 2015, amfAR provided $850,000 of renewal ARCHE funding to a consortium of European researchers who aim to replicate the case of the "Berlin patient," the first and only person known to have been cured of HIV. Diagnosed with leukemia, the patient was given a stem cell transplant with a twist: the cells he received were taken from a donor with a rare genetic mutation conferring resistance to HIV infection. Led by Dr. Javier Martinez-Picado of IrsiCaixa in Spain and Dr. Annemarie Wensing of University Medical Center Utrecht in the Netherlands, the team has already identified a group of patients who have undergone transplants and continues to monitor their progress in the hopes of generating new knowledge that can inform more widely applicable interventions. amfAR also awarded a $672,000 ARCHE grant in June to support a research team led by Dr. Timothy Schacker of the University of Minnesota, Minneapolis. Schacker is collaborating with a pair of leading investigators from the amfAR Institute for HIV Cure Research, Drs. Steven Deeks and Peter Hunt of the University of California, San Francisco (UCSF), to address one of the greatest challenges in HIV cure research: how to establish whether a person has been cured. Mathilde Krim Fellowships In October 2015, amfAR awarded a total of $600,000 in Mathilde Krim Fellowships in Basic Biomedical Research, an annual initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The program, which was created in 2008 in honor of amfARs founding chairman, has achieved spectacular results, including numerous published studies in major scientific journals. Each Krim Fellow receives $150,000 in funding over two years. Dr. Luis Agosto of Boston Medical Center is exploring one of the mechanisms that perpetuates the viral reservoir, with the goal of understanding how the virus evades the immune system. Dr. Liang Shan of Yale University in New Haven, CT, is using a humanized mouse model to test the efficacy of latency reversing drugs, studying their ability to reactivate HIV so that the immune system can kill those cells that harbor the virus. Dr. Louise Scharf of the California Institute of Technology in Pasadena is studying the molecular structure of broadly neutralizing antibodies isolated from two HIV-infected patients to better understand how these powerful antibodies can help in the development of a vaccine against the virus. And Dr. Amit Sharma of the Fred Hutchinson Cancer Research Center in Seattle, WA, is investigating how rhesus macaques can be better utilized as an animal model in HIV vaccine studies. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In FY2016, 64 scientific publications resulted from amfAR-funded research. Examples include: Harnessing the Power of Antibodies Writing in the May issue of the journal Science, amfAR Krim Fellow Dr. Stylianos Bournazos and associates reported using a single broadly neutralizing anti-HIV antibody to target infected CD4 T cells in mice with a humanized immune system (i.e., mice that have been injected with human stem cells). Working i |
| Program Service Accomplishments (2) | Line 4b: TREAT ASIA: amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 19 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced a record 34 publications in peer-reviewed medical journals in 2016. In 2016, amfAR successfully re-competed for funding for a new five-year cycle (2016-2021) that will be supported by the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), and for the first time the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA). The renewal application includes multiple studies that will be conducted across 58 institutions in 13 countries. The studies will help the program address emerging and critical issues facing people living with HIV who are transitioning from pediatric to adolescent care, and aging into older adults. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from approximately 9,000 patients at 20 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. In FY2016, the IeDEA consortium funded the second year of a study aiming to measure and better understand treatment adherence among young people with HIV. The study, which was conducted at the three participating IeDEA sites in Kenya, South Africa, and Thailand, evaluated factors that increase the risk of non-adherence and assessed the impact on treatment failure and clinic dropout. TREAT Asia Pediatric Network TREAT Asia's Pediatric Network includes 19 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult database and includes data from approximately 6,000 pediatric patients in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. TREAT Asia has been following a prospective cohort of 248 HIV-infected adolescents to evaluate multiple social, cultural, and behavioral factors that affect treatment adherence using an audio computer-assisted self-interview (ACASI) instrument at nine TApHOD sites in Malaysia, Thailand, and Vietnam. Among the study findings so far are that adolescents with effective virologic suppression are less likely to report high-risk sexual behaviors, such as inconsistent condom use. This emphasizes the need to promote and support strategies to achieve viral suppression as a key priority for adolescents who are struggling to adhere to antiretroviral therapy. This study was supported by the AIDS Life Foundation. Additional Adolescent Research In 2016, amfAR was awarded a Developmental Research Grant by the National Institutes of Health to improve how data on adolescents living with HIV are collected in resource-limited settings. The co-Principal Investigators- Treat Asia Director Dr. Annette Sohn and Dr. Mary-Ann Davies of the University of Cape Town, South Africa - are leading a team to establish a data collection and management platform that can guide clinical programs as to the socio-economic, clinical, and laboratory data needed to characterize how adolescents with HIV are transitioning to adult HIV care. The initiative, called GRADUATE: a Global fRAmework of Data collection Used for Adolescent HIV Transition Evaluation, will be implemented in Malawi, South Africa, and Thailand over the next two years. Expanding Pre-Exposure Prophylaxis (PrEP) for Female Sex Workers in Thailand In 2016, amfAR funded a study to assess combination HIV prevention needs, including pre-exposure prophylaxis (PrEP), among female sex workers in Bangkok and Pattaya, Thailand. The research team brings together experts from the Service Workers in Group (SWING) Foundation, a Thai advocacy organization for sex workers; Institute for Population and Social Research at Mahidol University in Bangkok; Johns Hopkins Bloomberg School of Public Health in Baltimore, MD; and amfAR. The researchers have collected data using focus groups, key informant interviews, and a questionnaire among 180 female sex workers to examine PrEP knowledge and acceptability and to document behavioral, social, and structural factors known to place women at risk for HIV. Addressing Unmet Needs in HIV Care In January 2016, TREAT Asia embarked on a think tank project to identify and address gaps in the management of HIV in Asia. The project is bringing together over 20 experts in HIV and other sub-specialties from Australia, China and Hong Kong SAR, India, Indonesia, the Philippines, South Korea, Taiwan, Thailand, Cambodia, Japan, Malaysia, and Vietnam. The think tanks are focusing on three priority areas: HIV and cardiovascular disease, HIV and liver disease, and HIV and drug resistance. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community-friendly" educational brochures on HIV treatment standards in local languages. In February and May 2016, TREAT Asia held two Youth ACATA (Asia Community for AIDS Treatment and Advocacy) workshops in Bangkok for young people living with HIV from Cambodia, Indonesia, and Thailand. In 2013, approximately 190,000 children and adolescents were living with HIV in the region. Launched in 2015 with support from ViiV Healthcares Positive Action for Adolescents program, Youth ACATA aims to educate participants about HIV and antiretroviral therapy and connects them to other HIV-positive youth in the region. In December 2015, Adams Love, the online HIV outreach initiative targeting gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) cut the ribbon on its new clinic in the heart of Bangkok. The clinic, established with support from amfAR, aims to appeal to discreet, harder-to-reach GMT individuals who might be hesitant to visit public government clinics for HIV testing and care. Part of an amfAR Implementation Science study, it will test three innovative HIV outreach and care models- each targeting a different subset of the GMT population. In addition, TREAT Asia continued to publish lay-language articles on AIDS research, policy, and community issues facing the TREAT Asia network and the Asia-Pacific as a whole. The articles and educational pieces appear in the TREAT Asia Report, a bimonthly e-newsletter, and on TREAT Asias website, www.treatasia.org. Treating HIV and Hepatitis C Co-Infection In May, TREAT Asia co-sponsored a one-and-a-half-day training in Bangkok for clinicians on treating hepatitis C and HIV co-infection with direct-acting antivirals (DAAs). More than 30 primary care and infectious disease physicians, patients, and treatment access advocates from six countries in South and Southeast Asia attended. The agenda included understanding steps for diagnosing hepatitis C infection, managing treatment side effects, and reviewing clinical care and treatment responses among people who inject drugs. TREAT Asia conducted the training in collaboration with the International Network for Hepatitis in Substance Users (INHSU) and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Expanded Access to Hepitatis C Treatments In August, TREAT Asia hosted its fourth regional strategic meeting on hepatitis C virus treatment access in Bangkok, with 22 participants from Cambodia, China, Indonesia, India, Malaysia, Nepal, Thailand, and Vietnam. The meeting included representatives from key population regional networks, including Mdecins Sans Frontires (MSF) Access Campaign, the Drugs for Neglected Diseases Initiative (DNDi), and the Lawyers Collective (a public interest service provider in India). Participants agreed to work with national partners to increase access to direct-acting antivirals by reducing regulatory barriers and ensuring affordable pricing. 15th Annual Network Meeting The 2015 TREAT Asia Annual Network Meeting was held Oct |
| Program Service Accomplishments (3) | Line 4c: PUBLIC INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 45,000 people; the TREAT Asia Report, an e-mail newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 100,000 people. The Foundation's website features news, interviews, blog posts, and original articles covering AIDS research, policy, the global epidemic, and amfAR programs and activiites. The website attracts an average of 40,000 visitors per month. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images on Instagram from fundraising and program events. amfAR has 72,000 likes on Facebook, 40,000 Twitter followers, and more than 108,000 Instagram followers. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS-related press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR staff and spokespeople-were carried in numerous media outlets, including the New York Times, Forbes, The Advocate, CBS Radio, Reuters, Bloomberg News, and the South China Morning Post. Celebrity Support amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone. In 2016, a collection of 1980s classic hits was updated by contemporary artists for The Time is Now!, a 14-track compilation album to benefit amfAR. The album features a soulful rendition of Michael Jacksons "Billie Jean" by singer-songwriter Aloe Blacc and a rendition of New Order's "Bizarre Love Triangle" performed by Sugar for Sugar, consisting of Scarlett Johansson, Julia Haltigan Holly Miranda, and Kendra Morris. The band Lower Dens, pop rock group DNCE, Dita Von Teese and Sebastien Tellier, and songwriting duo Marian Hill are also featured on the album. Other celebrity supporters included amfAR Ambassadors Milla Jovovich, Michelle Yeoh, and Cheyenne Jackson, Kathy Bates, Angela Bassett, Julia Roberts, Matt Bomer, Jamie Lee Curtis, Diane von Furstenberg, Gwyneth Paltrow, Chiara Ferragni, Ryan Murphy, Kevin Spacey, Lady Gaga, Diane Kruger, Uma Thurman, Dame Helen Mirren, Faye Dunaway, Katy Perry, Kate Moss, Marc Jacobs, Ricky Martin, amfAR Trustee Jay Ellis, Lea Michele, Michelle Rodriguez, Whoopi Goldberg, amfAR Trustee Harry Belafonte, Naomi Campbell, Heidi Klum, Riccardo Tisci, Adrien Brody, Eva Longoria, Harvey Keitel, Harvey Weinstein, Leonardo DiCaprio, Robert De Niro, Robin Thicke, Andrea Bocelli, Dean and Dan Caten, Chris Tucker, Jennifer Garner, Donatella Versace, and Carine Roitfeld. |
| Program Service Accomplishments (4) | Line 4d: THE GMT INITIATIVE: Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing funding for prevention and treatment services; and worked to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS. In September 2015, amfAR awarded an 18-month grant to the Kirby Institute at the University of New South Wales in Sydney, Australia, to extend the Opposites Attract Study underway in Brazil and Thailand. The study is being led by Dr. Andrew E. Grulich of The Kirby Institute and is evaluating the role of combination antiretroviral therapy as a "treatment of prevention" strategy among serodiscordant male homosexual couples in Australia, Brazil, and Thailand. The same funding was used to support clinics at the Instituto de Pesquisa Clnica Evandro Chagas (IPEC) in Rio de Janeiro and the Thai Red Cross AIDS Research Centre in Bangkok, which have been participating in the study since May 2014. Implementation Science Awards In FY2016, amfARs grant making through the GMT Initiative evolved to support larger implementation science projects aimed at identifying barriers to HIV testing, treatment, and care and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR has awarded $2.6 million over three years to support three such studies. Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the effectiveness of HIV self-testing done in the privacy of ones home, point-of-care CD4 testing, and the use of "peer navigators" familiar with the local health system to help those newly diagnosed gain access to HIV treatment and care. In Lima, Peru, Dr. Javier Lama of Asociacin Civil Impacta Salud y Educacin and his team are aiming to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care. Working in collaboration with the Boston-based Fenway Institute and two community GMT organizations, IMPACTA and EPICENTRO, Dr. Lama and his team are integrating routine cross-sex hormone therapy into HIV and sexually transmitted infection prevention, testing, and treatment services and implementing health services and peer case management for 200 transgender women. And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre are working to show how innovative technologies such as GMT-targeted websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs. Working in collaboration with Adams Love, a web-based health platform for GMT individuals, and two community-based organizations (Service Workers in Group/SWING and The Rainbow Sky Association of Thailand), the team are comparing the effectiveness of online services and support interventions with traditional clinic-based HIV services, and a hybrid model that combines elements of both strategies. amfAR HIV Scholars Program In FY2016, amfAR supported four young researchers from Paraguay, Brazil, South Africa, and Indonesia undergoing five months of graduate-level public health study at the Center for LGBT Health Research of the Graduate School of Public Health at the University of Pittsburgh as part of the amfAR HIV Scholars Program. The program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many from seeking HIV testing and services. The 2016 amfAR HIV Scholars are Dr. Antonio Spagnolo of the National University of Asuncin in Paraguay; Daniel Dutra de Barros of Santa Casa de So Paulo School of Medical Sciences in Brazil; Kabelo Maleke of Project Boithato at the Anova Health Institute in rural South Africa; and Adi Nugroho of the GWL-INA Network in Jakarta, Indonesia. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations about the spread of HIV among GMT individuals and to advocate for effective strategies to address it, amfAR publishes a range of reports on HIV and GMT. In November 2015, amfAR - along with the International AIDS Vaccine Initiative (IVAI), the Johns Hopkins University- Center for Public Health and Human Rights (JHU-CPHHR), and the United Nations Development Program (UNDP)- released updated guidelines to Respect, Protect, Fulfill, a document that offers practical advice on how to engage gay men and other MSM in epidemiologic and intervention research, including HIV prevention and treatment trials. First released in 2011, the guidance helps researchers and community-based organizations maximize the benefits and minimize any potential risks of working together on critically needed research involving this population. The revised Respect, Protect, Fulfill was compiled through a participatory process that enlisted input from researchers and community leaders and organizations throughout the world. |
| Program Service Accomplishments (5) | Line 4d: public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the U.S. National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the epidemic in the U.S., where more than 1.2 million people are living with the virus. In February 2016, amfAR published an infographic titled, Small Increase, Big Impact, illustrating the declining purchasing power of the National Institutes of Healths (NIH) HIV/AIDS research dollars. In 2016, the NIH budget was increased by $2 billion, and President Obama proposed a further increase of $825 million for 2017. However, HIV research funding remained at 2015 levels. An increase in HIV research funding in line with the increase in total NIH funding would have meant an additional $76.6 million for HIV research for 2017. Such an increase would have allowed the NIH to fund 180 HIV/AIDS studies that could significantly advance HIV prevention, treatment or cure research; fund 51 clinical trials focused on curing HIV; or fund a breakthrough prevention trial. Key Populations amfAR is dedicated to addressing the needs of the people most vulnerable to HIV infection: men who have sex with men, sex workers, people who inject drugs, and transgender people. In October 2015, amfAR published Towards Defining an HIV Implementation Science Agenda for Key Populations in Low- and Middle-Income Countries based on a meeting the Foundation hosted in May 2015 to brainstorm how implementation science research might improve HIV outcomes for key populations in resource-limited settings. While significant progress has been made in the fight against AIDS, there remains a considerable gap between the potential of existing prevention and treatment tools and their actual impact on people affected by the virus. amfAR published Following the Money to Key Populations, National Priorities, and Evidence-Based Budgeting in June, a qualitative assessment of how Kenya and South Africa use health data for budgetary resource allocation. The Foundation, along with the Centre for Economic Governance and AIDS in Africa (CEGAA) and AVAC, reviewed resource allocation for health and HIV interventions, identified epidemiological data currently in use, highlighted information and procedural gaps in resource allocation for key populations, and developed recommendations for future research. In July, amfAR published the report Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden? based on an evaluation of the U.S. Presidents Emergency Plan for AIDS Relief (PEPFAR). Worldwide, 40-50% of all HIV infections in adults aged 15-49 occur among key populations. The report concluded that the disproportionate HIV risk along with poor quality health services underscore the continuing importance of prioritizing resources and targeted interventions. Global Health In FY2016, amfAR published The World Without PEPFAR, an infographic highlighting significant advances in global HIV/AIDS treatment and prevention made possible by the U.S. Presidents Emergency Plan for AIDS Relief (PEPFAR). Launched in 2003, PEPFAR made billions of dollars available for HIV programs in developing countries and fundamentally changed the course of the global epidemic. amfAR also added new features and data to its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFARs planned funding of HIV/AIDS activities from 2007 to 2015. Launched in 2015, the database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders access and understand PEPFARs programs and priorities on a deeper level than was possible using other platforms. |
| Policies | form 990, part vi, section b Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 - AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. |
| Disclosure | Form 990, Part VI, Section C LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. |
| Functional Expenses | Part IX, Lines 1 & 3 The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F. |
| OTHER CHANGES IN NET ASSETS | FORM 990, SECTION XI, LINE 9 CHANGE IN VALUE OF THIRD PARTY TRUST......... $2,183 ------- TOTAL LINE 9 $2,183 |
| Software ID: | |
| Software Version: |